Skip to cohort results

Back to home

Episteme: Reactorfield outcome

Read the Cohort 1 case studies

Cohort 1: AI for science results

Reactorfield Outcome

Used agentic swarm to fix public neuroscience simulation software and increased neural simulations from 12 weekly to 100s per week.

Zachary Miller
Zachary Miller presents the increase in in-silico experiments enabled by his research workflow.

Company information

Episteme is a new R&D institution, co-founded by Louis Andre and Sam Altman, backed by SoftBank's Masayoshi Son.

More info about Episteme
  • It brings exceptional researchers, long-horizon funding, and operating infrastructure under one roof to pursue high-impact work across physics, biology, neuroscience, and engineering, modeled on Bell Labs and Xerox PARC.
  • The team includes veterans of the Gates Foundation, DeepMind, and government ARPA agencies.
Zachary Miller
Read the case study: Episteme’s Zachary Miller Scaled to Hundreds of Neural Simulations. (opens in a new tab)

Reactorfield Outcome

Uncovered hidden assumptions and missing controls in scientists’ experiments, potentially saving months of R&D.

Pradeep Ramesh
Pradeep Ramesh presents examples of missing controls and experimental assumptions surfaced by Tenzing.

Company information

Merge Labs is a research lab building higher bandwidth, less-invasive brain-computer interfaces that connect with neurons using molecules instead of electrodes, transmit and receive information using deep-reaching modalities like ultrasound, while avoiding implants into brain tissue.

  • Merge Labs was co-founded by leading BCI researchers, Sam Altman, Alex Blania, and Sandro Herbig.
More info about Merge Labs
  • OpenAI and Bain Capital led Merge's $250M seed round which also included investments from Interface Fund, Fifty Years, and Valve co-founder Gabe Newell.
Pradeep Ramesh
Read the case study: Merge Labs’ AI Interviewer Caught Missing Controls in Brain–Computer Interface Experiments, Potentially Saving Months of R&D (opens in a new tab)

Reactorfield Outcome

Discovered new pathways to produce rare nuclear isotopes (2 preprints published) with strong cancer therapy potential.

Jason Parisi, Kyle Schiller
Two isotope-production pathways and the corresponding preprints, presented by Jason Parisi.

Company information

Marathon Fusion produces the world’s most valuable isotopes with compact, commercial fusion reactors.

  • Founded by a team from SpaceX, Schmidt Futures and Princeton, Marathon is supported by $18m in funding and revenue across the US Department of Energy, the UK Atomic Energy Authority, and leading private investors.
More info about Marathon Fusion
  • Company calculations show that power plants using its approach could generate roughly 5,000 kg of gold per year per gigawatt of output.
Jason Parisi, Kyle Schiller
Read the case study: Marathon Fusion Develops AlphaFold for Nuclear Physics, then Publishes Two Preprints on Production Routes for Cancer-Therapy Isotopes (opens in a new tab)

Reactorfield Outcome

Caught gaps in drug-testing procedures using 700+ quality and regulatory documents.

Yuuki Hosokawa
Yuuki Hosokawa presents documentation issues caught by an AI reviewer before final approval.

Company information

Retro Biosciences is a clinical-stage longevity company aiming to add ten healthy years to human life.

  • Backed with a $180 million check from Sam Altman in 2022, it has since raised at a reported $1.8 billion valuation.
More info about Retro Biosciences
  • Its lead oral program, RTR242, is designed to restore autophagy and entered Phase I testing in Austria in 2025.
Yuuki Hosokawa
Read the case study: Retro Biosciences’ AI Reviewer Saved Time and Flagged Issues Before Drugs Reach Humans (opens in a new tab)

Reactorfield Outcome

Discovered new material to prevent reactor shutdowns and improve reaction yield.

Dan Bullard, Zach Detweiler, Alex Fisher
Dan Bullard presents calcium hexaluminate as a candidate reactor material identified with Claude.

Company information

Radify Metals is rebuilding a critical-minerals supply chain through the conversion of metal oxides into high-purity metal.

  • The company has raised just under $3 million from Overture, Founders Inc., Mana Ventures, and Acequia Capital.
More info about Radify Metals
  • Its modular hydrogen-plasma reactors transform rare-earth and other critical-mineral oxides directly into metal. Radify is building a flexible domestic metallization platform that could make critical-metal production faster, cleaner, and more resilient, directly targeting a supply chain in which China currently controls roughly 87% of global rare-earth refining capacity.
Dan Bullard, Zach Detweiler, Alex Fisher
Read the case study: Radify Debugged Stalled Reactors, Identified New Materials, and Cleared Five Weeks of Data in 48 Hours (opens in a new tab)

Reactorfield Outcome

Simulated, developed, and validated protein binders for brain-cancer 2 weeks instead of months.

Andrew Bartynski
Andrew Bartynski presents a protein-validation workflow accelerated from months to two weeks.

Company information

Kopra Bio is a YC-backed oncology company developing viral immunotherapies that turn cancer cells into local factories for their own destruction.

  • The UCSF spinout closed a $9.1M seed co-led by Boutique Venture Partners.
More info about Kopra Bio
  • Its first focus is glioblastoma, one of the most lethal and immunologically resistant cancers. In preclinical mouse models, Kopra pushed survival rates from 0% in controls to 90% in treated animals, with durable remissions and immunologic memory. Kopra is translating that viral-immunology foundation into a new approach to solid tumors.
Andrew Bartynski
Read the case study: Kopra Bio Cut Protein Validation From Months to Two Weeks and Reported Binding Hits (opens in a new tab)

Reactorfield Outcome

Cut pharma drug analysis and processing time from 25 minutes to 25 seconds.

Oleg Yerov
Oleg Yerov demonstrates the reduction from 25 minutes to 25 seconds.

Company information

Xilio Therapeutics is a clinical-stage immuno-oncology company engineering cancer therapies to activate chiefly inside tumor microenvironments.

  • Publicly traded on Nasdaq (XLO), Xilio has raised over $200M to date.
More info about Xilio Therapeutics
  • In August 2026, the FDA cleared its IND for XTX501 as a potential foundational backbone therapy for solid tumors, with a Phase 1/2 trial starting in the second half of 2026.
Oleg Yerov
Read the case study: Xilio Scientist With No Coding Experience Cut a 25-Minute Analysis to 25 Seconds (opens in a new tab)

Reactorfield Outcome

Built a system that delivers real time, source-backed, in vivo CAR-T data for researchers & stakeholders.

Dan Hartman, Rio Boothello
Dan Hartman presents a shared research tool for in vivo CAR-T development.

Company information

Strand Therapeutics is an MIT spinout building programmable mRNA medicines.

  • Its total funding exceeds $250 million, including Regeneron Ventures, ICONIQ, Amgen Ventures, the family office of former J&J CEO Alex Gorsky, and Eli Lilly.
More info about Strand Therapeutics
  • The company combines targeted lipid nanoparticles, microRNA-responsive safety circuits, and self-replicating or circular RNA to address mRNA's central challenges of targeting, safety, and durability.
  • Its lead IL-12 program, presented at the 2025 ASCO Annual Meeting, has shown early clinical activity in advanced solid tumors.
Dan Hartman, Rio Boothello
Read the case study: Strand Therapeutics Used AI to Automate Five Hours of Weekly In Vivo CAR-T Research and Cut Answer Times to Minutes (opens in a new tab)

Reactorfield Outcome

Delivered a 12-page NIH grant, in 1 hour instead of 8 weeks, leveraging his existing history of experimental data & publications.

Brian S. Kim
Northwell’s later scientifically audited grant draft: 14 pages, five figures, and 11 verified citations; 1.8% of text changed by hand.

Company information

Dr. Brian S. Kim, MD, is Northwell Health's Chief Biotech Officer.

  • Northwell Health is New York's largest health system and employer, serving over 3M patients annually.
More info about Northwell Health
  • Brian contributed to two FDA-approved treatments, authored more than 190 publications, holds multiple patents, and co-founded three biotech companies. He has been continuously funded by the NIH since 2011.
Brian S. Kim
Read the case study: Northwell’s Brian Kim Drafted a 12-Page NIH Grant in One Hour of Active Work (opens in a new tab)

Reactorfield Outcome

Discovered novel mRNA treatment to reverse aging in human lungs, then invested >$100k in this new candidate.

Vera Mucaj
Vera Mucaj shares feedback from scientists who selected an unexpected intervention combination.

Company information

Vera Mucaj, PhD, is an EIR at Mayo Clinic, where she helps turn leading clinical science into new ventures.

  • Previously, Vera was Datavant's Chief Scientific Officer and employee #8. She led the life sciences product portfolio and founded the clinical trials business, which was adopted in over 250 trials by most top 20 pharma and biotech companies.
Vera Mucaj
Read the case study: Vera Mucaj’s mRNA Explorer Led to Over $100,000 invested in Mayo Clinic Lung Transplantation Experiments (opens in a new tab)

Reactorfield Outcome

Cut part-design reviews, for complex parts manufacturing, from 3–4 hours to minutes. Boosting turn around time 10x.

Jakob Knudsen
Jakob Knudsen demonstrates a CAD review flagging an unmanufacturable internal corner.

Company information

Foundation Industries is modernizing the way frontier-hardware teams get parts made.

  • The YC-backed manufacturer delivers rapid domestic CNC machining, including two-day turnaround, through a software-native workflow connecting CAD upload, specifications, quoting, payment, and production tracking. They will serve in the long term as the physical world API for the frontier.
Jakob Knudsen
Read the case study: Foundation Industries Used AI to Cut Part Reviews for Drones, Robots and Jets From Hours to Minutes (opens in a new tab)

Reactorfield Outcome

Cut magnet-defect tagging from 4 hours to 15 minutes, catching hard-to-see flaws.

Matthew Groll, Eric Silver
Matthew Groll presents automated defect detection and a 15-minute review of magnet samples.

Company information

Mass Magnetics is a YC-backed startup building high-performance permanent magnets domestically from recycled rare-earths.

  • The founders previously built battery pilot-production lines and materials-science labs for NASA, Draper Labs, and MIT.
Matthew Groll, Eric Silver
Read the case study: Mass Magnetics Used AI to Cut Magnet Defect Tagging From Four Hours to 15 Minutes, Catching Flaws the Human Eye Would Miss (opens in a new tab)